nach oben

Erschienen in:

20.09.2018 | Topic Paper

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

verfasst von: Axel S. Merseburger, Andrea B. Apolo, Simon Chowdhury, Noah M. Hahn, Matthew D. Galsky, Matthew I. Milowsky, Daniel Petrylak, Tom Powles, David I. Quinn, Jonathan E. Rosenberg, Arlene Siefker-Radtke, Guru Sonpavde, Cora N. Sternberg

Erschienen in: World Journal of Urology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

The SIU (Société Internationale d’Urologie)–ICUD (International Consultation on Urologic Diseases) working group on systemic therapy for metastatic bladder cancer has summarized the most recent findings on the aforementioned topic and came to conclusions and recommendations according to the evidence published. In Europe and the United States, treatment for metastatic UC has changed a great deal recently, mainly involving a move from chemotherapy to immune checkpoint blockers. This is particularly true in platinum-refractory disease, where supportive randomized data exist. Five checkpoint blockers have been approved in this setting by the FDA: avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab. Nivolumab, pembrolizumab, and atezolizumab have been approved in Europe.

Sternberg CN, Yagoda A, Scher HI et al (1989) Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448–2458CrossRefPubMed

Loehrer PJ Sr, Einhorn LH, Elson PJ et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066–1073CrossRefPubMed

von der Maase H, Hansen SW, Roberts JT et al (2000) Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077CrossRefPubMed

Sternberg CN, de Mulder PH, Schornagel JH et al (2001) Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor vs. classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19:2638–2646CrossRefPubMed

McConkey DCW, Shen Y, Lee I, Porten S, Matin S, Kamat A, Corn P, Millikan R, Dinney C, Czerniak B, Siefker-Radtke A (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Eurol 69:855–862CrossRef

Choueiri TK, Jacobus S, Bellmunt J et al (2014) Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 32:1889–1894CrossRefPubMedPubMedCentral

Plimack ER, Hoffman-Censits JH, Viterbo R et al (2014) Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 32:1895–1901CrossRefPubMedPubMedCentral

Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30:1107–1113CrossRefPubMedPubMedCentral

Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506–513CrossRefPubMed

10.

De Santis M, Bellmunt J, Mead G et al (2012) Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191–199CrossRefPubMed

11.

Hainsworth JD, Meluch AA, Litchy S et al (2005) Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer 103:2298–2303CrossRefPubMed

12.

Oing C, Rink M, Oechsle K et al (2016) Second line chemotherapy for advanced and metastatic urothelial carcinoma. vinflunine and beyond: a comprehensive review of the current literature. J Urol 195:254–263CrossRefPubMed

13.

Powles T, Duran I, van der Heijden MS et al (2018) Atezolizumab vs. chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748–757CrossRefPubMed

14.

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026CrossRefPubMedPubMedCentral

15.

Balar AV, Galsky MD, Rosenberg JE et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67–76CrossRefPubMed

16.

O’Donnel P, Grivas P, et al. (2017) Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). 2017 ASCO Annual Meeting Genitourinary (nonprostate) cancer oral abstract session: June 2017

17.

Balar AV, Castellano D, O’Donnell PH et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483–1492CrossRefPubMed

18.

Chang R, Shirai K (2016) Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep 2016:bcr2016216426CrossRefPubMedPubMedCentral

19.

Cavalcante L, Amin A, Lutzky J (2015) Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. Cancer Manag Res 7:47–50CrossRefPubMedPubMedCentral

20.

Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026CrossRefPubMedPubMedCentral

21.

Powles T, Loriot Y, Duran I, et al. (2017) IMvigor211: A phase III randomized study examining atezolizumab vs. chemotherapy for platinum-treated advanced urothelial carcinoma. EAS Congress:abstr

22.

Sharma P, Retz M, Siefker-Radtke A et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312–322CrossRefPubMed

23.

Apolo AB, Infante JR, Balmanoukian A et al (2017) Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase Ib Study. J Clin Oncol 35:2117–2124CrossRefPubMedPubMedCentral

24.

Powles T, O’Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 3:e172411CrossRefPubMedPubMedCentral

25.

Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920CrossRefPubMedPubMedCentral

26.

Joaquim Bellmunt RDW, Vaughn David J, Fradet Yves, Lee Jae-Lyun, Fong Lawrence, Vogelzang Nicholas J, Climent Miguel A, Petrylak Daniel Peter, Choueiri Toni K, Necchi Andrea, Gerritsen Winald, Gurney Howard, Quinn David I, Culine Stephane, Sternberg Cora N, Nam Kijoeng, Frenkl Tara L, Perini Rodolfo F, Bajori Dean F (2018) Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs. investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). ASCO J Clin Oncol 36(6_suppl):410CrossRef

27.

Powles T, Smith K, Stenzl A et al (2017) Immune checkpoint inhibition in metastatic urothelial cancer. Eur Urol 72:477–481CrossRefPubMed

28.

Bellmunt J, Theodore C, Demkov T et al (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454–4461CrossRefPubMed

29.

Garcia-Donas J, Font A, Perez-Valderrama B et al (2017) Maintenance therapy with vinflunine plus best supportive care vs. best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. Lancet Oncol 18:672–681CrossRefPubMed

30.

McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853–1857CrossRefPubMed

31.

Vaughn DJ, Broome CM, Hussain M et al (2002) Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937–940CrossRefPubMed

32.

Loriot Y DI, Ravaud A, et al. (2017) Phase III randomized study examining atezolizumab vs. chemotherapy for platinum-treated advanced urothelial carcinoma. EACR-AACR-SIC 2nd Special Conference

33.

Albers P, Park SI, Niegisch G et al (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term vs. prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22:288–294CrossRefPubMed

34.

Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104:1627–1632CrossRefPubMed

35.

Pagliaro LC, Millikan RE, Tu SM et al (2002) Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol 20:2965–2970CrossRefPubMed

36.

Dreicer R, Li H, Cooney MM et al (2008) Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer 112:2671–2675CrossRefPubMed

37.

von der Maase H, Lehmann J, Gravis G et al (2006) A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 17:1533–1538CrossRefPubMed

38.

Kattan J, Culine S, Theodore C et al (1993) Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann Oncol 4:793–794CrossRefPubMed

39.

Lee JH, Kang SG, Kim ST et al (2014) Modified MVAC as a second-line treatment for patients with metastatic urothelial carcinoma after failure of gemcitabine and cisplatin treatment. Cancer Res Treat 46:172–177CrossRefPubMedPubMedCentral

40.

Gondo T, Ohori M, Hamada R et al (2011) The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen. Int J Clin Oncol 16:345–351CrossRefPubMed

41.

Sonpavde G, Pond GR, Choueiri TK et al (2016) Single-agent taxane vs. taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69:634–641CrossRefPubMed

42.

Raggi D, Miceli R, Sonpavde G et al (2016) Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27:49–61CrossRefPubMed

43.

Geldart T, Chester J, Casbard A et al (2015) SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. Eur Urol 67:599–602CrossRefPubMedPubMedCentral

44.

Petrylak DP, Tagawa ST, Kohli M et al (2016) Docetaxel as monotherapy or combined with ramucirumab or icrucumab in second-line treatment for locally advanced or metastatic urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial. J Clin Oncol 34:1500–1509CrossRefPubMed

45.

Petrylak DP, de Wit R, Chi KN et al (2017) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet 390:2266–2277CrossRefPubMed

46.

Witte RS, Elson P, Bono B et al (1997) Eastern cooperative oncology group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589–593CrossRefPubMed

47.

Albers P, Siener R, Hartlein M et al (2002) Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma—prognostic factors for response and improvement of quality of life. Onkologie 25:47–52PubMed

48.

Lorusso V, Pollera CF, Antimi M et al (1998) A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on bladder cancer. Eur J Cancer 34:1208–1212CrossRefPubMed

49.

Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993–2998CrossRefPubMed

50.

Pectasides D, Aravantinos G, Kalofonos H et al (2001) Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 12:1417–1422CrossRefPubMed

51.

Sweeney CJ, Roth BJ, Kabbinavar FF et al (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24:3451–3457CrossRefPubMed

52.

Galsky MD, Mironov S, Iasonos A et al (2007) Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25:265–270CrossRefPubMed

53.

Dreicer R, Li S, Manola J et al (2007) Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 110:759–763CrossRefPubMed

54.

Winquist E, Vokes E, Moore MJ et al (2005) A Phase II study of oxaliplatin in urothelial cancer. Urol Oncol 23:150–154CrossRefPubMed

55.

Vaughn DJ, Srinivas S, Stadler WM et al (2009) Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 115:4110–4117CrossRefPubMed

56.

Culine S, Theodore C, De Santis M et al (2006) A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395–1401CrossRefPubMedPubMedCentral

57.

Beer TM, Goldman B, Nichols CR et al (2008) Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy. Clin Genitourin Cancer 6:36–39CrossRefPubMed

58.

Witte RS, Manola J, Burch PA et al (1998) Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs 16:191–195CrossRefPubMed

59.

Dreicer R, Li H, Stein M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115:4090–4095CrossRefPubMed

60.

Gallagher DJ, Milowsky MI, Gerst SR et al (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28:1373–1379CrossRefPubMed

61.

Necchi A, Mariani L, Zaffaroni N et al (2012) Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol 13:810–816CrossRefPubMed

62.

Pili R, Qin R, Flynn PJ et al (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11:477–483CrossRefPubMedPubMedCentral

63.

Jones RJ, Hussain SA, Protheroe AS et al (2017) Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer. J Clin Oncol 35:1770–1777CrossRefPubMed

Titel: SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer
verfasst von: Axel S. Merseburger
Andrea B. Apolo
Simon Chowdhury
Noah M. Hahn
Matthew D. Galsky
Matthew I. Milowsky
Daniel Petrylak
Tom Powles
David I. Quinn
Jonathan E. Rosenberg
Arlene Siefker-Radtke
Guru Sonpavde
Cora N. Sternberg
Publikationsdatum: 20.09.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 1/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2486-1

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer

Abstract

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

Functional follow-up after Advance® and Advance XP® male sling surgery: assessment of predictive factors

Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer

How bothersome double-J ureteral stents are after semirigid and flexible ureteroscopy: a prospective single-institution observational study

Wake-up call for more doctor–patient communication and an increase in public information campaigns on the risk factor of smoking with regard to the development and prognosis of bladder cancer

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie